For more information, visit Basuch.com Important Risk Information Prescribing Information Visit Zirgan's website

Case #1 - Classic Herpes Dendrite Resolved in 5 days

A 47-year-old woman presented with ocular pain, conjunctival hyperemia, and corneal lesions with dendritic branching patterns. After diagnosing epithelial keratitis related to herpes simplex virus, the patient was prescribed topical Zirgan antiviral gel. Dr. Hovanesian shares the case details and talks about managing herpetic keratitis with Zirgan.

  • Bookmark
  • QuickLink

Indication ZIRGAN® is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Important Risk Information about ZIRGAN®

  • ZIRGAN® is indicated for topical ophthalmic use only.
  • Patients should not wear contact lenses if they have signs or symptoms of herpetic keratitis or during the course of therapy with ZIRGAN®.
  • Most common adverse reactions reported in patients were blurred vision (60%), eye irritation (20%), punctate keratitis (5%), and conjunctival hyperemia (5%).
  • Safety and efficacy in pediatric patients below the age of 2 years have not been established.

Please see the full prescribing information for ZIRGAN® here.

For more information about treating herpes simplex epithelial keratitis with ZIRGAN®, click here.

ZIRGAN is a registered trademark of Laboratoires Théa Corporation licensed by Bausch & Lomb Incorporated.

©2012 Bausch & Lomb Incorporated.
PH4428 2/12

Comments (0)